Removal selectivity of Prometheus: A new extracorporeal liver support device

Figure 1 The albumin fraction of the patient’s blood is filtered through an albumin-permeable membrane (AlbuFlow^®) into a secondary circuit. There, the separated albumin fraction is purified by direct adsorption of albumin-bound toxins using one or two adsorbers (Prometh01^® and Prometh02^®). The plasma is then pumped back into the primary circuit where a conventional high-flux dialysis (FX 50) is performed.

Figure 2 (A₁-A₂) Course of plasma bile acids and urea concentrations before, during and after 2 d of Prometheus^® therapy. Data are presented as median, quartiles, and minimum/maximum values. (B_1-B₂) Course of plasma TNF-α and IL-6 concentrations before, during and after 2 d of Prometheus^® therapy. Data are presented as median, quartiles, and minimum/maximum values. (C_1-C₃) Course of antithrombin 3, factors II and V levels before, during and after 2 d of Prometheus^® therapy. Data are presented as median, quartiles, and minimum/maximum values. (D_1-D₃) Course of plasma total protein, albumin, and fibrinogen before, during, and after 2 d of Prometheus^® therapy. Data are presented as median, quartiles, and minimum/maximum values.